Fullerenols Inhibit Ferroptosis to Prevent Cisplatin-Induced Acute Kidney Injury

Study Background and Research Question

Acute kidney injury (AKI) is a clinical syndrome marked by a rapid decline in renal function, leading to high morbidity and mortality worldwide. Despite significant research, there are currently no definitive treatments to reverse or halt AKI progression, in part due to its complex pathophysiology and the diversity of causative factors, including drug toxicity, ischemia, and sepsis (reference paper). Recent evidence has positioned ferroptosis—a regulated, iron-dependent form of non-apoptotic cell death characterized by lipid peroxidation—as a key driver in the development of AKI, particularly in response to nephrotoxic agents such as cisplatin. Given the unique iron-handling mechanisms and susceptibility to redox imbalance in renal tissue, the targeting of ferroptosis-associated pathways represents a promising therapeutic avenue for AKI intervention. The present study addresses whether fullerenols, a class of polyhydroxylated fullerene nanoparticles known for their free radical scavenging properties and biocompatibility, can serve as effective ferroptosis inhibitors to mitigate cisplatin-induced AKI.

Key Innovation from the Reference Study

The central innovation of this work lies in the identification and mechanistic validation of fullerenols as efficient ferroptosis inhibitors in a clinically relevant model of AKI. Unlike conventional antioxidants that may have limited efficacy in modulating ferroptotic cell death, fullerenols demonstrate broad-spectrum suppression of both lipid peroxidation and iron accumulation—two defining hallmarks of ferroptosis (reference paper). The study provides evidence that fullerenols not only neutralize reactive oxygen species (ROS) but also modulate key enzymatic and molecular regulators involved in the ferroptotic cascade.

Methods and Experimental Design Insights

The investigators implemented a multifaceted in vivo and in vitro experimental design:

• Mouse models of cisplatin-induced AKI were established to recapitulate the clinical features of drug-induced renal injury.
• Fullerenol nanoparticles were administered prophylactically, and renal function was assessed using standard markers (serum creatinine, urine output).
• Histological analyses were performed to evaluate tubular damage, iron deposition, and lipid peroxidation in kidney tissue.
• Biochemical assays and qPCR quantified the expression of ferroptosis-related enzymes (e.g., ACSL4, ALOXE3, POR) and antioxidant defense components (system Xc⁻, glutathione [GSH], GPX4).
• High-resolution imaging and iron assays assessed the extent of ferrous iron accumulation and membrane lipid damage.

These complementary approaches enabled mechanistic dissection of how fullerenols intervene at multiple nodes in the ferroptosis pathway.

Core Findings and Why They Matter

The study’s major findings are as follows:

• Suppression of Lipid Peroxidation: Fullerenols significantly reduced levels of malondialdehyde (MDA), a key marker of lipid peroxidation, in the kidneys of cisplatin-treated mice (reference paper).
• Reduction of Iron Accumulation: Treatment with fullerenols attenuated the accumulation of low-valent (ferrous) iron, a pro-oxidant catalyst in ferroptosis, as shown by decreased iron staining and lower mRNA expression of iron regulatory genes.
• Enzyme Modulation: Fullerenols inhibited cisplatin-induced upregulation of ACSL4, ALOXE3, and POR—enzymes implicated in promoting peroxidation of polyunsaturated fatty acids, a critical step in ferroptotic cell death.
• Antioxidant Defense Enhancement: The nanoparticles promoted expression and activity of system Xc⁻, GSH, and GPX4, reinforcing cellular antioxidant capacity.
• Functional Protection: Prophylactic administration of fullerenols preserved renal function and ameliorated histological damage in AKI mice.

These results collectively establish fullerenols as potent ferroptosis inhibitors, acting both upstream and downstream of ROS generation and iron dysregulation. Importantly, this mechanistic breadth distinguishes fullerenols from narrower antioxidant strategies and supports their translational potential for AKI prevention.

Protocol Parameters

• ferroptosis induction assay | cisplatin 20 mg/kg in mice | in vivo AKI model | recapitulates drug-induced renal ferroptosis | paper
• ferroptosis inhibition assay | fullerenol 20 mg/kg in mice | prophylactic AKI protection | demonstrates efficacy of fullerenol | paper
• oxidative stress assay | malondialdehyde (MDA) quantification | lipid peroxidation readout | surrogate endpoint for ferroptosis | paper
• iron accumulation assay | Perl’s Prussian blue staining | detection of ferrous iron in kidney | visualizes iron overload in AKI | paper
• gene expression analysis | qPCR for ACSL4, ALOXE3, POR | ferroptosis pathway modulation | tracks molecular response to intervention | paper
• alternative in vitro modeling | Erastin 10 μM for 24 h in tumor cells | ferroptosis induction | widely used to probe oxidative cell death | workflow_recommendation

Comparison with Existing Internal Articles

The mechanistic insights from this AKI-focused study resonate with prior literature utilizing Erastin as a prototypical ferroptosis inducer in cancer biology. For example, internal articles such as "Erastin and the Future of Ferroptosis: Mechanistic Insights" and "Erastin: Precision Ferroptosis Inducer for Advanced Cancer Models" provide detailed workflows for leveraging system Xc⁻ inhibition and oxidative stress assays in tumor systems, specifically in RAS/BRAF-mutant contexts. The current reference paper extends this mechanistic framework to the context of organ injury, demonstrating that core ferroptotic events—lipid peroxidation and iron overload—are not limited to oncology but are also central in acute renal pathology. This cross-domain convergence underscores the utility of shared markers (e.g., MDA, ACSL4) and assay designs across disease models.

Limitations and Transferability

Several limitations merit consideration:

• Model Specificity: While the study establishes efficacy in cisplatin-induced AKI, it remains to be seen whether fullerenol’s protective effects generalize to other etiologies of AKI (e.g., ischemia-reperfusion, sepsis).
• Translational Maturity: The findings are preclinical; clinical translation will require further validation of safety, pharmacokinetics, and dosing strategies in humans (reference paper).
• Mechanistic Breadth: Although fullerenols modulate multiple ferroptosis-associated pathways, off-target or pleiotropic effects cannot be ruled out.
• Comparative Efficacy: Direct comparisons with other ferroptosis inhibitors or modulators, including small molecules like ferrostatin-1 or Erastin, were not performed in this study.

Transferability of the workflow is promising for research into other ferroptosis-driven pathologies, supported by the mechanistic overlap demonstrated in both cancer and renal injury models.

Research Support Resources

For researchers aiming to dissect ferroptosis mechanisms or model oxidative cell death in vitro, small molecule inducers such as Erastin (SKU B1524, APExBIO) are widely used. Erastin specifically inhibits system Xc⁻ and induces ferroptosis in RAS/BRAF-mutant cancer cells, serving as a standard tool for oxidative stress and cell death pathway studies (workflow_recommendation). For protocols involving Erastin, fresh DMSO stock solutions at ≥10.92 mg/mL are recommended, with typical cell-based assays employing 10 μM over 24 hours. Combining such inducers with antioxidant or ferroptosis-inhibiting agents (e.g., fullerenols) can facilitate comprehensive mechanistic evaluation of cell death pathways across oncology and organ injury models. For detailed mechanistic reviews and protocol tips, refer to relevant internal resources on Erastin’s role in ferroptosis research (see above).